SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

Apricus Biosciences, Inc. (APRI)

APRI RSS Feed
Add APRI Price Alert      Hide Sticky   Hide Intro
Moderator: Dimitrios George, carlodb1978, mecosmo2
Search This Board:
Last Post: 9/26/2016 12:01:56 PM - Followers: 191 - Board type: Free - Posts Today: 0

Apricus Biosciences, Inc. (APRI) 

 

 

http://www.apricusbio.com/

 

 

 

 

Company Address:

11975 El Camino Real, Suite 300
San Diego, CA 92130
T (858) 222-8041

 CIK:   0001017491

Apricus Website:    http://www.apricusbio.com/index.html

 

 
 

NexACT® - Multi-Route Drug Delivery Technology

NexACT® Multi-Route drug delivery technology facilitates compounds crossing the lipid bilayer and yet biodegrades in vivo to natural amino acids and natural fatty acids.

This technology is useful for:
  • Penetrating, proprietary, topical & transdermal formulations.
    Improving oral bioavailability of poorly soluble, poorly permeating compounds (BCS class 2-4)
    Delivering siRNA therapeutics into the cells; in vivo validated
    Development of more effective, penetrating cosmeceutic formulations
    Preservative

The safety and permeation properties of this proprietary drug delivery technology was demonstrated in the Vitaros® product which was approved for the treatment of erectile dysfunction in November 2010 by Health Canada, and approved by the European Union in June 2013.  Vitaros has been launched in all European Union countries by partner pharmaceutical companies.  Additional agreements for marketing Vitaros have been established.  For more information see the company's most recent 10K SEC filing.

In September 2015 the company anounced an agreement with Allergan to reacquire marketing rights for Vitaros in the U.S.  The company expects to resubmit a filing for FDA approval of Vitaros in the second half of 2016.  For more information see the company's most recent 10K SEC filing.


The company expects to initiate a Phase IIb clinical trial for RayVa to treat Reynaud's Syndrome in the second half of 2016.

In October 2014, the company acquired U.S. development and licensing rights to Fispemifene, a Selective Estrogen-Receptor Modulator (SERM) for treatment of secondary hypogonadism.  In March 2016 the company discontinued development Fispemifene after disappointing Phase IIb results.
.

 Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001017491&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Share Structure:
Outstanding Shares
 61,78M

Authorized Shares
75,000,000
  

Investor Relations:
ir@apricusbio.com
Tel: +1-858 222-8041

Matthew Beck
The Trout Group
:(646)378 2933

 

 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
APRI
Current Price
Volume:
Bid Ask Day's Range
SureTrader
APRI News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 09/26/2016 05:11:59 PM
APRI News: Current Report Filing (8-k) 09/26/2016 05:09:16 PM
APRI News: Apricus Biosciences Announces $4.6 Million Registered Direct Offering 09/23/2016 08:00:30 AM
APRI News: Apricus Biosciences Announces $4.6 Million Registered Direct Offering 09/23/2016 08:00:00 AM
APRI News: Apricus Biosciences Announces the Launch of VitarosĀ® in the Czech Republic and Slovakia by Recordati 09/21/2016 07:00:17 AM
News News Alert: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 09/26/2016 05:11:59 PM
PostSubject
#26083   Thanks for posting Rogerthat1 09/26/16 12:01:56 PM
#26082   I spoke to Matt Beck of investor relations mean gene 09/26/16 11:59:02 AM
#26081   Hi north. Good to see you here Rogerthat1 09/26/16 11:38:22 AM
#26080   Anyway, whatever casino is going to say, we carlodb1978 09/26/16 11:37:32 AM
#26079   You might have to pay for that premium north40000 09/26/16 11:23:34 AM
#26078   It won't let me ignore casino lol Aprilov 09/26/16 11:21:03 AM
#26077   Click on their IHUB handle, and then click north40000 09/26/16 11:19:35 AM
#26076   If you're free account you may have maxed Rogerthat1 09/26/16 11:19:03 AM
#26075   Can someone direct me how to put someone Aprilov 09/26/16 11:14:53 AM
#26074   The word is Denner passed and Aspire passed casinokid11211 09/26/16 10:35:15 AM
#26073   The investor relation once said they did not carlodb1978 09/26/16 10:33:23 AM
#26072   I agree Denner had to be part of eicoman 09/26/16 10:30:13 AM
#26071   I would think that Pasco would have gotten mean gene 09/25/16 05:56:17 PM
#26070   That would be a fortune if there is carlodb1978 09/25/16 10:06:25 AM
#26069   Wow, did Pascoe stick it to Denner and casinokid11211 09/25/16 08:09:20 AM
#26068   China and Mexico would be very nice also !!!! Aprilov 09/24/16 11:01:08 AM
#26067   FDA approval is just about everything, I agree eicoman 09/24/16 10:55:28 AM
#26066   All about the FDA , nothing else matters... Aprilov 09/24/16 09:51:27 AM
#26065   the key is US NDA we will cease binchey 09/24/16 09:17:22 AM
#26064   also they have enough cash now to get eicoman 09/24/16 08:19:19 AM
#26063   catalysts to get the PPS over $1: eicoman 09/24/16 08:07:58 AM
#26062   R/S is possible, they are counting on NOV eicoman 09/24/16 08:03:02 AM
#26061   Pascoe stuck it to you guys again. casinokid11211 09/24/16 07:48:45 AM
#26060   no doubt a r/s will be next,,too many kingsransome 09/24/16 06:17:36 AM
#26059   I hope so, we'll have to keep an eicoman 09/23/16 07:29:52 PM
#26058   * * $APRI Video Chart 09-23-16 * * ClayTrader 09/23/16 05:15:57 PM
#26057   35¢ will be the floor here beginning next Rogerthat1 09/23/16 05:11:41 PM
#26056   good point almost, sarissa has 14M, there's alot eicoman 09/23/16 04:50:40 PM
#26055   I agree, that is a real risk in eicoman 09/23/16 04:49:43 PM
#26054   Either way I'm fine with it Aprilov 09/23/16 02:45:33 PM
#26053   They want to file asap after FDA meeting Rogerthat1 09/23/16 02:44:36 PM
#26052   Not this early they could have easily waited Aprilov 09/23/16 02:41:42 PM
#26051   You don't think they needed cash? With upcoming Rogerthat1 09/23/16 02:40:33 PM
#26050   I don't think this was a cash panic Aprilov 09/23/16 02:19:07 PM
#26049   Close sarissa aowns almost 15 million plus their Chillin up north 09/23/16 02:05:41 PM
#26048   I will add more next week as I dave86 09/23/16 01:44:47 PM
#26047   Do these new guys now own as much Aprilov 09/23/16 01:03:52 PM
#26046   This must be all retail and shorts selling Rogerthat1 09/23/16 12:15:58 PM
#26045   Likely needed cash for NDA re-sub. Picked up Rogerthat1 09/23/16 12:02:16 PM
#26044   I think these new investors are privvy to Aprilov 09/23/16 11:48:36 AM
#26043   yes, good news / bad news, low price, eicoman 09/23/16 11:08:24 AM
#26042   This offering basically says Denner has written off casinokid11211 09/23/16 10:13:24 AM
#26041   me too... carlodb1978 09/23/16 10:09:41 AM
#26040   Why 35 cents though and not higher? tjguy 09/23/16 09:59:42 AM
#26039   YES! I added more this is a buying mecosmo2 09/23/16 09:51:24 AM
#26038   Why 35 cents though and not higher? They dave86 09/23/16 09:49:36 AM
#26037   More dilution, more cash for APRI. growtheport 09/23/16 09:47:45 AM
#26036   And I am referring to this deal from july: PuuliTuku 09/23/16 09:41:57 AM
#26035   Is this the earlier deal with sarissa or PuuliTuku 09/23/16 09:37:09 AM
#26034   Nov 17 Aprilov 09/23/16 09:17:36 AM
PostSubject